Literature DB >> 8795590

How should cancer presenting as a malignant pleural effusion be managed?

H Bonnefoi1, I E Smith.   

Abstract

The objective of the study was to review the natural history of patients with a malignant pleural effusion but without obvious evidence of a primary, to assess the value of investigations used to look for a primary and to assess the response to palliative chemotherapy. This was done by a retrospective study of patients' notes at the Lung Unit, Royal Marsden Hospital, Sutton, Surrey. Improvement in tumour-related symptoms (and duration) on chemotherapy was assessed by the patient before the first course of chemotherapy and following each course using simple descriptive criteria as follows: (1) complete disappearance of symptoms (CR); (2) good improvement in symptoms (PR); (3) minor or no change in symptoms (NC); (4) worse symptoms (PD). Pleural effusion objective response (and duration) according to Hamed definition: success defined as a continued absence of reaccumulation of pleural fluid on all follow-up radiographs; any reaccumulation was regarded as a treatment failure. Overall survival was measured from the date of histological/cytological diagnosis to death. The study included 42 patients, 27 males and 15 females with a median age of 55 years. A primary was found in 15 patients (36%), and considered to be lung cancer. A total of 11/32 (34%) had a thoracic computed tomography (CT) scan with abnormalities compatible with a diagnosis of lung primary. When thoracic CT scan was negative, fibre optic bronchoscopy was always negative (0/13). Abdominal and pelvic CT scan, abdominal ultrasound, pelvic ultrasound and mammograms failed to reveal the primary. Twenty-three patients underwent local treatment and 37 received systemic chemotherapy. A total of 29/37 (78%) patients achieved symptomatic improvement (median duration, 6 months) and 32/37 (86%) an objective response of their pleural effusion on chemotherapy (median duration, 6 months). The median survival of the whole group was 12 months (3-60+ months). In this series the thoracic CT led to a diagnosis of lung primary in 34% of the cases. Other radiological examinations and bronchoscopy were unhelpful. Chemotherapy achieved symptom relief in 78% of patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8795590      PMCID: PMC2074707          DOI: 10.1038/bjc.1996.444

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline.

Authors:  J C Ruckdeschel; D Moores; J Y Lee; L H Einhorn; I Mandelbaum; J Koeller; G R Weiss; M Losada; J H Keller
Journal:  Chest       Date:  1991-12       Impact factor: 9.410

2.  A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer.

Authors:  I S Fentiman; R D Rubens; J L Hayward
Journal:  Eur J Cancer Clin Oncol       Date:  1986-09

3.  Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens.

Authors:  R L Woods; R M Fox; M H Tattersall; J A Levi; G N Brodie
Journal:  N Engl J Med       Date:  1980-07-10       Impact factor: 91.245

4.  Use of selected combinations of monoclonal antibodies to tumor associated antigens in the diagnosis of neoplastic effusions of unknown origin.

Authors:  M Mottolese; I Venturo; R P Donnorso; C G Curcio; M Rinaldi; P G Natali
Journal:  Eur J Cancer Clin Oncol       Date:  1988-08

5.  Pleuroperitoneal shunt for recurrent malignant pleural effusions.

Authors:  V Tsang; H C Fernando; P Goldstraw
Journal:  Thorax       Date:  1990-05       Impact factor: 9.139

6.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

7.  Pleuro-peritoneal shunting. Alternative therapy for pleural effusions.

Authors:  A G Little; M H Kadowaki; M K Ferguson; V M Staszek; D B Skinner
Journal:  Ann Surg       Date:  1988-10       Impact factor: 12.969

8.  The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions.

Authors:  D Sears; S I Hajdu
Journal:  Acta Cytol       Date:  1987 Mar-Apr       Impact factor: 2.319

9.  Fiberoptic bronchoscopy and pleural effusion of unknown origin.

Authors:  S H Feinsilver; A A Barrows; S S Braman
Journal:  Chest       Date:  1986-10       Impact factor: 9.410

10.  Comparison of intracavitary bleomycin and talc for control of pleural effusions secondary to carcinoma of the breast.

Authors:  H Hamed; I S Fentiman; M A Chaudary; R D Rubens
Journal:  Br J Surg       Date:  1989-12       Impact factor: 6.939

View more
  4 in total

Review 1.  Management of lung cancer.

Authors:  A Melville; A Eastwood
Journal:  Qual Health Care       Date:  1998-09

2.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

3.  Efficacy of recombinant adenoviral human p53 gene in the treatment of lung cancer-mediated pleural effusion.

Authors:  Kun-Lin Li; Jun Kang; Peng Zhang; L I Li; Yu-Bo Wang; Heng-Yi Chen; Yong He
Journal:  Oncol Lett       Date:  2015-03-18       Impact factor: 2.967

4.  An update in the management of malignant pleural effusion.

Authors:  Dk Muduly; Svs Deo; Ts Subi; Aa Kallianpur; Nk Shukla
Journal:  Indian J Palliat Care       Date:  2011-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.